What does this research mean for the field?

SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists offer convergent and complementary cardiorenal protective mechanisms in diabetic kidney disease, providing a biological rationale for combination therapies. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Synthesize mechanistic and clinical evidence on the convergent and complementary cardiorenal-metabolic effects of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease.

August 22, 2026Diabetology & Metabolic SyndromeOpen Access

Convergent and complementary cardiorenal protective mechanisms of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease within the CKM framework

Q: What is the clinical evidence from this study?

Study design: Review. Population: Diabetic kidney disease. Intervention: SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists.

View Full Paper

Ask AI

Bookmark

Key result

SGLT2 inhibitors, GLP-1 RAs, and finerenone provide complementary cardiorenal benefits in diabetic kidney disease.

Why the study?

Diabetic kidney disease is a leading cause of cardiorenal morbidity and mortality, and synthesizing evidence on the convergent and complementary mechanisms of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRAs is needed to guide precision combination therapy.

Design

Review

Authors

ZJZhuoran JiaAnhui Medical University PZPeiyang ZhengAnhui Medical University XWXiaohe WuNanjing University of Science and Technology

Discussion

Member takes

Implication

Supports complementary use in diabetic kidney disease; leaves open optimal combinations for prospective trials.

Key Points

Synthesize mechanistic and clinical evidence on the convergent and complementary cardiorenal-metabolic effects of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
Conducted a narrative review synthesizing mechanistic pathways and randomized outcome trial evidence for SGLT2 inhibitors, GLP-1 receptor agonists, and the non-steroidal mineralocorticoid receptor antagonist finerenone.
Evaluated molecular convergence, class-specific strengths, and biological rationales for dual- and triple-pathway combinations within the cardiovascular-kidney-metabolic framework.
Demonstrated that the three drug classes converge on shared downstream mechanisms: restoring hemodynamic homeostasis, attenuating inflammation and oxidative stress, preserving mitochondrial integrity, and suppressing maladaptive fibrosis.
Identified distinct complementary strengths, with SGLT2 inhibitors showing prominent benefits in heart failure and renal progression, GLP-1 receptor agonists excelling in weight reduction and atherosclerotic risk, and finerenone blocking mineralocorticoid receptor-driven inflammation and fibrotic injury.

Structured PICO

Population

Patients with diabetic kidney disease (DKD) and related cardiovascular-kidney-metabolic (CKM) phenotypes, including heart failure, obesity, and high cardiovascular risk

Intervention

SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists (finerenone)

This review provides a mechanistically integrated framework supporting the convergent and complementary cardiorenal-metabolic benefits of SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone in diabetic kidney disease.

Limitations

Efficacy and safety of SGLT2 inhibitors in patients receiving dialysis, with kidney transplantation, or very advanced kidney failure remain incompletely defined.
The relative contribution of tubuloglomerular feedback versus direct tubular protection in humans is still debated.
The extent to which renal benefit of GLP-1 receptor agonists depends on direct receptor-mediated effects within kidney tissue versus systemic metabolic improvement remains uncertain.

Cite This Study

Jia et al. (2026) conducted a review in Diabetic kidney disease. SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists was evaluated. SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone provide convergent and complementary cardiorenal-metabolic benefits in diabetic kidney disease through shared downstream mechanisms.

synapsesocial.com/papers/6a895fe4ca7ade938187ee81 https://doi.org/10.1186/s13098-026-02284-z

View Full Paper

Ask AI

Bookmark

Convergent and complementary cardiorenal protective mechanisms of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease within the CKM framework

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Convergent and complementary cardiorenal protective mechanisms of SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in diabetic kidney disease within the CKM framework

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider